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ABSTRACT
Muscle injuries among athletes require a complete recovery to be able to function optimally as before.
However, in spite of implementing the management with PRICE (Protection, Rest, Immobilization,
Compression and Elevation), during the recovery processes, fibrotic tissue will be formed, which
is an unwanted non-functional muscle. Losartan is a blood pressure-lowering drug which has the
inhibitory effect of inhibitory effect of TGF-β cytokines (fibrotic tissue regulators). TGF-β is the key
to fibrotic formation and differentiation. Losartan has an effect on decreasing the TGF-β production
and it may affect the fibrotic tissue. This research is conducted by an experimental comparative method
on the rabbit as study objects. Based on Federer formula sampling, twenty samples totally occurred.
The random sampling method is adopted for comparing fibrotic tissue in two different groups (control
group and losartan group). Losartan is administered orally. There were significant differences in the
proportion of fibrotic tissue between the sample groups. The losartan group showed that the level
of fibrotic intensity, distribution, and H-score was decreased compared to the control group.
Moreover, the result of Mann Whitney statistic test, for determining the H-score for both groups,
showed that p is less than 0.05 (p<0.05), which implies that this research is statistically significant.
This research proves that giving Losartan tablets brings a significant impact in reducing the
formation of muscle fibrosis in muscle injury grade 1 in gastrocnemius rabbits.
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INTRODUCTION
Muscle injury grade 1 is a common injury which placed
up to 90% among all of the muscle injury (Medicine,
2012). The standard treatment for this injury is PRICE
(Protect, Rest, Ice, Compression, Elevation), yet
the healing process produces fibrotic tissues, which
increases the possibility of recurrences as the muscle
becomes weaker and less flexible (Nugroho, 2016).
In the last decade, the incidence of muscle injuries is
increasing. Muscle injuries divided into two based on
the mechanism, indirect and direct types. Direct type
is if there no direct external trauma appear (Ekstrand,
Askling, Magnusson, & Mithoefer, 2013). There are
either structural injuries due to longitudinal distraction
that make tears the muscle tissue or without evidence of
a tear (Ekstrand et al., 2013). The most common direct
case is because compressive to the thigh that usually
compresses the muscles structures. Different from
indirect type, muscle fibers usually are not torn. Direct
injuries, especially muscle contusion, are common in
sports, usually in high body contact sports types, such
as football, rugby, basketball, and others. This kind of
injury makes pain and may interfere joint motion of
the athletes after the healing process (Trojian, 2013).
Fibrotic tissue usually occurred after muscle injuries,
substitute the functional muscle fiber to suboptimal
E-ISSN 2477-0612

muscle function. It makes muscles group less flexible
and high risk to recurrence, in some case makes chronic
pain. Therefore, we develop the new treatment in the
management of muscle injury use Losartan drugs, this is
a pilot study to applied Losartan in athlete muscle injury.
Losartan is anti-hypertension drugs that widely known
as angiotensin II receptor blocker (ARB) type, effective
to decrease blood pressure with minimum complication
and can be used in all age groups. Also, effective to
treat cardiomyopathy and chronic renal disease. These
drugs causing directly vasodilation of periphery blood
vessel, and by reducing secreting of aldosterone and
vasopressin. Activation of receptor angiotensin II by
angiotensin II make production of thrombospondin-I,
this secreted glycoprotein have been shown to be the
regulator of TGF-β activation. Therefore, inhibition of
ATII and subsequences decreasing of TSP-1 will block
the TGF-β activation (Cohn et al., 2007).
Recent research shows the effectiveness of blocking
TGF-β production for fibrotic problems using antifibrotic agents, such as Decorin, Relaxin, and Suramin
have good results (Mann et al., 2011; Terada et al.,
2013). In Indonesia, this kind of drugs is difficult to
find, have an expensive price (0,5 – 2 USD/tablet) and
have a lot of complication (Yang et al., 2011). Other
research showed that Losartan also possesses the capacity
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of decreasing the TGF-β secretion over mice which
have Duchenne Muscular Dystrophy (DMD) (Meinen
et al., 2012; Pessina et al., 2014). TGF-β is cytokine
key to differentiate myoblast to become myofibroblast,
decreasing this cytokine will increase myocyte
(functional muscle cell) production.
METHODS
This research was conducted using the experimental
comparative method on the animal as study objects. The
random sampling method was adopted for comparing
quality and quantity value of the formation of fibrotic
tissue in two different groups with muscle injury grade I
based on histologic sampling and calculate with H-score.
The experiment was conducted in the Laboratory of
Medical Research Unit of our institution from April to
May 2016.
For this experiment, the subjects were rabbits which met
the inclusion criteria: adult male rabbit, New Zealand
races, 7 months old, weight 1-1,5 kg. Drop out criteria
were decided as infection, fracture, dead rabbit, and
changes in animal behavior. Using Federer formula to
specify the number of samples needed, it was found
that the experiment was totally to have 20 rabbits. Each
group have 10 samples of rabbit.
To begin with, the muscle trauma was created on
each rabbit by employing a dropping mass technique,
which utilizing 1 kg load that was dropped from 0,5
meter high on the rabbits’ gastrocnemius muscle, then
bandaged using circular casts. Shortly afterwards, the
research subjects were divided into two groups, the first
group is the control group and the second group is the
losartan treatment rabbits group. Group 1 as a control
group was not administered losartan, while group 2 as

Figure 2. Muscles with moderate fibrotic intensity

Figure 3. Muscles with strong fibrotic intensity
treatment group was administered with losartan 25 mg/
KgBW using the small orogastric tube.
The research procedure included preparations of
muscle injury using drop mass technique, circular cast,
inserting losartan (25 mg/KgBW) for three weeks, then
harvest of the gastrocnemius muscle, and histopathology
Hematoxylin-Eosin and Van Goisson Staining Protocol
Goisson examination were done in the Department of
Pathology Anatomy. Then, the evaluation of fibrotic
intensity and distribution was done by an anatomical
pathologist.

Figure 1. Muscles without fibrotic area

Histopathology measurement was done using the Histoscore system. This score is divided into 2 subjects, fibrotic
intensity and fibrotic distribution. The range of fibrotic
scoring is 0-3, score 0 if there are no fibrotic tissue (Figure
1), score 1 if the fibrotic intensity is weak, score 2 for
moderate fibrotic intensity (Figure 2), and score 3 for strong
moderate intensity (Figure 3), while fibrotic distribution
was divided into 4 groups, with range 1-4. Score 1
E-ISSN 2477-0612
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Table 1. Fibrotic intensity, fibrotic distribution, and
H-Score in control group
Sample

No

Group I 1
2
3
4
5
6
7
8
9
10

Fibrotic
Intensity
3
3
2

Fibrotic
Distribution
2
1
2

H-Score

Variable

8
4
6

Fibrotic Intensity

2
3
3
2
3
2
2

2
2
1
2
1
1
2

6
8
4
6
4
3
6

Mean

5.5

Table 2. Fibrotic intensity, fibrotic distribution, and
H-Score in Losartan treatment group
Sample

No Fibrotic
Intensity
Group 2 1
3

Fibrotic
Distribution
1

H-Score
4

2

3

1

4

3

3

1

4

4

0

0

0

5

0

0

0

6

0

0

0

7
8

0
0

0
0

0
0

9

0

0

0

10

0

0

0

Mean

1.2

Instensity+1)

x

Mild
Moderate
Strong
None
Fibrotic Distribution

0 (0,0%)
5 (25.0%)
8 (40.0%)
7 (35.0%)

0
<20%
20-50%
51-80%
>80%
H-Score Fibrotic
Mean±STD
Median
Range (min-max)

7 (35.0%)
7 (35.0%)
6 (30.0%)
0 (0,0%)
0 (0,0%)
3.3500±2.833
4.000
0.00-8.00

Table 1 and 2 showed the results of this study. There
was decreasing mean of fibrotic tissue formation in
muscle healing after blunt trauma, the mean control
group is 5,5 and mean for treatment group is 1,2.

Later, the results of the special staining of the two groups
were compared using the scoring of the H-score system :
H-Score = (Fibrotic
Distribution.

N= 20

RESULTS

if the fibrotic distribution is less than 20%, score 2
if the fibrotic distribution within 20-50%, score 3 if
the fibrotic distribution is 51-80%, and score 4 if the
fibrotic distribution more than 80% (Gal et al., 2008).

Fibrotic

This score has a range from 2 to 16. Afterwards, the data
collection and statistical analysis were carried out by
using Kolmogorov-Smirnov and Mann-Whitney tests
with p<0.05 for significant differences.

E-ISSN 2477-0612

Table 3. Characteristic of result sample group (control
and Losartan treatment group)

Table 3 below explained the overall characteristic of all
fibrotic intensity, fibrotic distribution, and H-score in
both groups. From the experiment, it was found that
5 samples (25.0%) showed moderate intensity, 8
samples (40.0%) indicated strong fibrotic intensity, and
7 samples (35.0%) did not have fibrotic. The mean for
H-Score was 3.3500±2.833.
The data was analyzed using Kolmogorov-Smirnov
statistical test (Table 4). The result was p = 0.015
(significant if p<0.05). It shows that there were
meaningful differences in the proportion of fibrotic
intensity and fibrotic distribution variable.
Meanwhile, Mann-Whitney analysis was used to
calculate the distribution of H-score, as the data was
abnormal. From the formula, as seen in Table 5, it
resulted that fibrotic H-score was p = 0.0001 (significant
if p<0.05). This, therefore, concluded that there were
significant differences in the mean between 2 sample
groups.

Pharm Sci Res, Vol 6 No 1, 2019

The Effectivity of Losartan

49

Table 4. Kolmogorov Smirnov result
Variable

Group 1
N= 10

Fibrotic Intensity
Mild
Moderate
Strong
None
Fibrotic Distribution
0
<20%
20-50%
51-80%
>80%

Group
Group 2
N= 10

P Value
0.015**

0 (0.0%)
5 (50.0%)
5 (50.0%)
0 (0.0%)

0 (0.0%)
0 (0.0%)
3 (30.0%)
7 (70.0%)
0.015**

0 (0.0%)
4 (40.0%)
6 (60.0%)
0 (0.0%)
0 (0.0%)

7 (70.0%)
3 (30.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)

Group 1: Control Group; Group 2: Losartan Treatment Group
Significant value if p<0.05. Marker** showed p-value <0.05,
concluded significant differences in proportion.

Table 5. Mann Whitney H-Score Result
Variable

Group
Group 1
N= 10

Group 2
N= 10

H-Score Fibrosis
Mean±STD
Median

5.500±1.7159
6.000

1.200±1.932
0.000

Range (min-max)

3.00-8.00

0.00-4.00

P Value
0.0001**

Group 1: Control Group; Group 2: Losartan Treatment Group
Significant value if p<0.05. Marker** showed p-value <0.05,
concluded significant or meaningful in the statistic

DISCUSSION
Investigation anti-fibrotic properties of angiotensin
receptor type I blocker (ARB) in muscle healing from
previous studies showing effects on myocardial and
smooth muscle tissue injury. The role of angiotensin
II in muscle fibrotic after injury is well documented in
the cardiac literature, where angiotensin II antagonists
with ARBs are noted to significantly improve cardiac
contractility and cardiac output (Gremmler et al.,
2000). The histologic analysis also suggests that
heart repair mechanisms are associated with decreased
fibrosis and enhanced regeneration. The effects of ARB
on skeletal muscle healing, however, remain largely
unstudied.

also increases the chance of re-rupture. As we know, TGF-β
cytokines is a regulator for fibrotic tissue production,
which transform myoblast into myofibroblast, which
is then differentiated to become fibrotic tissue in chronic
muscle pathology (Meinen et al., 2012). Although TGF-β
blocking substances have already been found and known
for its effectiveness in fibrotic tissue problems, such as
Decorin, Suramin, and Relaxin (Mann et al., 2011; Terada
et al., 2013), yet these drugs are not yet openly distributed
in Indonesia, which makes it quite expensive and mostly
requires injection use. Losartan is thus chosen for its ability
to decrease TGF-β cytokine and its well-availability in all
age group (Cohn et al., 2007). We hypothesized, that
Losartan would improve the muscle healing process in
acute muscle injury by decreasing fibrotic tissue.

The fibrotic formation is the main problem to be solved in
the muscle healing process, with the main intention is to
maximize muscle’s functional healing. This suboptimal
healing makes muscles weaker and less flexible, and it

Losartan tablet is an ARB drug which is commonly used
for hypertension. Receptor angiotensin Type 1 regulates
Thrombospondin (TSP 1) where the TSP 1 is the controller
of TGF-β production. Losartan inhibits the activity of
E-ISSN 2477-0612
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Figure 4. Losartan effect to the acute muscles injury
angiotensin, thus decrease the TGF-β cytokines production
then decreasing of fibrotic tissue formation (Figure 4).
The measurement of the fibrotic intensity and fibrotic
distribution, obtained in the experiment, were done by
anatomy pathologist before converted to the H-score.

treatment accelerated the functional recovery of the
muscle after injury and, more importantly, this treatment
could be readily applied clinically.

The statistic result for H-score was p = 0.0001 (significant
if p < 0.05), which showed that there was a significant
difference between the H-Score of the control group and
the H-score of the administered group. As a finding of this
research (see table 4), Losartan tablets gives significant
influence in the fibrotic formation on acute muscle injury
grade 1. It is similar to Meinen research which had a
conclusion that Losartan could decrease fibrotic tissue but
in chronic muscle pathology (Meinen et al., 2012).

This research was approved by Ethical Committee with
letter no. LB04.01/A05EC/049/11/2016.

This finding may clinically fascinate anti-fibrotic therapy
and potentially developed so far for healthy individuals
with an acute skeletal muscle injury.

The authors declare that they have no conflict of interest.

Clinical trials on losartan as an anti-fibrotic agent
to promote optimal muscle healing is not yet clear,
therefore it is important to pay attention to its potential
disadvantages effects of angiotensin II receptor
antagonist. The adverse effect profile of ARB is very
minimal compared to other antihypertensive drugs;
dose-related side effects are hypotension, whereas
non-dose related adverse include headaches, dizziness,
weakness, and fatigue (Aronson, 2015).

Aronson, J. K. (2015). Meyler’s side effects of drugs:
the international encyclopedia of adverse drug reactions
and interactions: Elsevier.

CONCLUSION

Ekstrand, J., Askling, C., Magnusson, H., & Mithoefer,
K. (2013). Return to play after thigh muscle injury in
elite football players: implementation and validation
of the Munich muscle injury classification. Br J Sports
Med, bjsports-2012-092092.

In summary, we have demonstrated in rabbits model
that losartan treatment regimen can improve overall
skeletal muscle healing after a muscle contusion injury
by inhibiting the development of fibrosis. Losartan
E-ISSN 2477-0612
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